Abstract
Substance use disorder (SUD) is a global health problem with significant impact on individuals and society. The presentation of SUD is diverse, involving various substances, ages at onset, comorbid conditions, and disease trajectories. Current treatments for SUD struggle to address this heterogeneity, resulting in high relapse rates. SUD often co-occurs with other psychiatric and mental-health related conditions that contribute to the heterogeneity of the disorder and predispose to adverse disease trajectories. Family and genetic studies highlight the role of genetic and environmental factors in the course of SUD, and point to a shared genetic liability between SUDs and comorbid psychopathology. In this study, we aimed to disentangle SUD heterogeneity using a deeply phenotyped SUD cohort and polygenic scores (PGSs) for psychiatric disorders and related traits. We explored associations between PGSs and various SUD-related phenotypes, as well as PGS-environment interactions using information on lifetime emotional, physical and/or sexual abuse. Our results revealed different patterns of associations between the genetic liability for mental-health related traits and SUD-related phenotypes, which may help explain part of the heterogeneity observed in SUD. In our SUD sample, we found associations linking the genetic liability for ADHD with lower educational attainment, the genetic liability for PTSD with higher rates of unemployment, the genetic liability for educational attainment with lower rates of criminal records and unemployment and the genetic liability for well-being with lower rates of outpatient treatments and fewer problems related to family and social relationships. We also found evidence of PGS-environment interactions showing that genetic liability for suicide attempt worsened the psychiatric status in SUD individuals with a history of emotional physical and/or sexual abuse. Collectively, these data contribute to a better understanding of the role of the genetic liability for mental health-related conditions and adverse life experiences in SUD heterogeneity.
Competing Interest Statement
J.A.R.Q was on the speakers bureau and/or acted as consultant for Biogen, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Rubio, Uriach, Technofarma and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubio, Shire, Takeda, Shionogi, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen- Cilag, Shire, Oryzon, Roche, Psious, and Rubio. All other authors declare no biomedical financial interests or conflicts of interest.
Funding Statement
This work was supported by the Agencia de Gestio Ajuts Universitaris i de Recerca (AGAUR 2017SGR-1461 2021SGR-00840 and 2021-SGR-01093) the Instituto de Salud Carlos III (P19/01224 PI20/00041 PI22/00464 and FI18/00285 to L.V.R CP22/00128 to M.S.A and CP22/00026 to S.A) the Ministry of Science Innovation and Universities (IJC2018-035346-I to M.S.A RYC2021-031324-I to J.C.D and PID2021-1277760B-I100 to B.C. and N.F-C.) the Ministry of Health Social Services and Equality (PNSD-2020I042 to N.F-C.) the Network Center for Biomedical Research (CIBER) to J.C.D. the European Regional Development Fund (ERDF) the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN) the ECNP Network ADHD across the Lifespan La Marato de TV3 (202228-30 and 202228-31) and ICREA Academia 2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The project was approved by the Ethics Committee at the Hospital Universitari Vall d Hebron.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Materials and analysis code for this study are available by emailing upon request
